Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasNeuro-OncologyDiseaseAcute Lymphoblastic LeukaemiaMalignant MeningitisNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellPrimary Lymphoma of the CNSSubgroupB-ALLLymphomatous MeningitisICD10C79.3C83.-C83.3C83.7C85.9C91.0-MeSHBurkitt LymphomaLymphoma, Large B-Cell, DiffuseMeningeal CarcinomatosisSequenceDA-EPOCH-R(R), Burkitt's lymphomaR-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).STUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DChemotherapyChemo-substanceCytarabineMethotrexateRituximabChemo-substanceCytarabineMethotrexateRituximabChemo-substanceCytarabineMethotrexateRituximabChemo-substanceCytarabineMethotrexateRituximabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateNo. Substances13912Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseReinductionTherapy intentioncurativepalliativeRisksEmetogenicityEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorAbramson JGriffin TCPfreundschuh MRoschewski MRubenstein JDiseaseaggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1Burkitt-Lymphom, ZNS-Befall vor Beginn der Therapiediffus großzelliges Non-Hodgkin-Lymphom, HochrisikoPrimär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2Wiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginCancer Center, Massachusetts General Hospital, BostonDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDSHNHL 2009-1, OPTIMAL > 60Lymphoid Malignancies Branch, National Cancer Institute, BethesdaMemorial Hospital of South Bend, South BendProtocols in Revision 5 protocols foundProtocols under revision.Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231 V1.1)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240 V1.1)Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001 V1.1)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133 V1.0)
